Every material Form 8-K Haemonetics has filed with the SEC since May 29, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Haemonetics reported second-quarter fiscal 2027 revenue of $357.8 million, up 9.3%, and GAAP earnings of $1.00 per diluted share, up from $0.81 a year earlier. The company raised its reported revenue growth guidance to 8% to 11% but narrowed its adjusted operating margin expansion guidance to 0 to 50 basis points from 50 to 100 basis points.
Q2 revenue $357.8 million, up 9.3%; organic revenue growth 10.0%
GAAP EPS $1.00 vs. $0.81 a year earlier; adjusted EPS $1.35, up 6.3%
Reported revenue guidance raised to 8% to 11% from 5% to 8%; adjusted operating margin expansion lowered to 0 to 50 basis points from 50 to 100
Haemonetics reported first-quarter fiscal 2027 revenue of $339.4 million, up 5.6%, with GAAP earnings of $0.72 per diluted share versus $0.70 a year earlier. The company raised its fiscal 2027 organic revenue growth guidance to 4% to 7% from 3% to 6%, though GAAP net income fell 3.0% to $33.0 million.
Q1 fiscal 2027 revenue was $339.4 million, up 5.6%; organic revenue growth was 5.9%.
GAAP diluted EPS was $0.72 versus $0.70; adjusted diluted EPS was $1.14, up 3.6%.
Organic revenue growth guidance was raised to 4% to 7% from 3% to 6%; reported revenue guidance was raised to 5% to 8% from 4% to 7%.
Free cash flow was $39.1 million, up $36.6 million; cash on hand was $223.4 million as of June 27, 2026.
Haemonetics' board elected Martin Madaus, a Carlyle Group Senior Operating Executive, as a director effective July 24, 2026. At the same meeting, shareholders re-elected eight directors, approved an advisory say-on-pay vote, ratified Ernst & Young LLP as auditor, and approved amended 2019 Long-Term Incentive Compensation and 2007 Employee Stock Purchase Plans. The plan changes authorize 4,680,000 additional shares under the incentive plan and extend both plans through 2036.
Martin Madaus elected director effective July 24, 2026; expected to join the Audit Committee and Governance and Compliance Committee
Non-employee director annual equity award with an approximate value of $200,000
Shareholders approved the incentive plan amendment, which authorizes 4,680,000 additional shares, with 37,730,923 votes for and 2,055,726 against
Ellen Zane, Christopher Simon and six other nominees re-elected for one-year terms expiring in 2027
Haemonetics reported fourth-quarter fiscal 2026 revenue of $346.4 million, up 4.8%, and adjusted earnings of $1.29 per diluted share, up 4.0%. A $77.2 million impairment of intangible assets tied to Attune Medical turned the quarter to a GAAP net loss of $20.1 million, or $(0.44) per share, and the company also issued fiscal 2027 guidance calling for reported revenue growth of 4% to 7%.
Q4 fiscal 2026 revenue of $346.4 million, up 4.8%; organic growth 4.5%, organic ex-CSL growth 8.6%
Q4 GAAP net loss of $20.1 million, or $(0.44) per share, versus net income of $58.0 million, or $1.17 per share, a year earlier
Fiscal 2026 revenue of $1.334 billion, down 2.0%; GAAP EPS $2.05 versus $3.31; adjusted EPS $4.96
Fiscal 2027 guidance: reported revenue growth 4% to 7%, organic growth 3% to 6%, adjusted operating margin expansion of 50 to 100 basis points
Haemonetics director Charles J. Dockendorff told the company on April 27, 2026 that he will not stand for re-election at the 2026 Annual Meeting of Shareholders. He will remain a director and keep his Audit and Governance and Compliance Committee roles until that meeting, and the filing says the decision is not the result of any disagreement with the company.
Charles J. Dockendorff informed the company on April 27, 2026 of his decision
He has served on the Board since 2014 and sits on the Audit Committee and Governance and Compliance Committee
He will serve until the 2026 Annual Meeting of Shareholders
The filing states the decision is not the result of any disagreement with the company
Haemonetics reported third-quarter fiscal 2026 revenue of $339.0 million, down 2.7% from a year earlier, while GAAP net income rose 19.3% to $44.7 million. The company raised its fiscal 2026 adjusted earnings per diluted share guidance to $4.90 to $5.00 from $4.80 to $5.00 and raised its free cash flow guidance to $200 million to $220 million from $170 million to $210 million.
Q3 revenue was $339.0 million, down 2.7%; organic revenue declined 1.2%, and organic ex-CSL revenue rose 7.5%.
GAAP earnings per diluted share were $0.95, up from $0.74; adjusted earnings per diluted share were $1.31, up 10.1%.
Q3 free cash flow was $74.2 million, up 150.9%; cash on hand was $363.4 million as of December 27, 2025.
Fiscal 2026 adjusted earnings per diluted share guidance now $4.90 to $5.00; free cash flow guidance now $200 million to $220 million.
Haemonetics reported second-quarter fiscal 2026 revenue of $327.3 million, down 5.3% from a year earlier, while GAAP net income rose 14.3% and adjusted earnings per diluted share rose 13.4% to $1.27. The company raised its fiscal 2026 adjusted earnings per diluted share guidance to $4.80 to $5.00 and its free cash flow guidance to $170 million to $210 million, and reaffirmed its adjusted operating margin guidance of 26% to 27%.
Q2 revenue was $327.3 million, down 5.3%; organic ex-CSL revenue grew 9.4%.
GAAP earnings per diluted share were $0.81, up from $0.66; adjusted earnings per diluted share were $1.27.
Fiscal 2026 adjusted EPS guidance raised to $4.80 to $5.00 from $4.70 to $5.00; free cash flow guidance raised to $170 million to $210 million from $160 million to $200 million.
Q2 operating expenses included $8.6 million of intangible asset impairment charges.
Haemonetics reported first-quarter fiscal 2026 revenue of $321.4 million, down 4.4% from a year earlier, and GAAP earnings of $0.70 per diluted share compared with $0.74 a year earlier. Adjusted earnings per diluted share rose 7.8% to $1.10, and the company reaffirmed its fiscal 2026 guidance, including adjusted earnings per diluted share of $4.70 to $5.00. For shareholders, the quarter shows lower reported revenue and GAAP profit alongside higher adjusted profit and an unchanged outlook.
Revenue was $321.4 million, down 4.4%; organic revenue rose 0.5% and organic ex-CSL revenue rose 12.9%
GAAP earnings per diluted share were $0.70 versus $0.74; adjusted earnings per diluted share were $1.10, up 7.8%
Adjusted gross margin was 60.8%, up 550 basis points; free cash flow was $2.5 million
Fiscal 2026 guidance reaffirmed: adjusted operating margin 26% to 27%, free cash flow $160 million to $200 million
Haemonetics reported fourth-quarter fiscal 2025 revenue of $330.6 million, down 3.7% from a year earlier, while GAAP earnings per diluted share rose to $1.17 from $0.40 and adjusted EPS rose 37.8% to $1.24. The company also issued fiscal 2026 guidance, including adjusted EPS of $4.70 to $5.00, and approved a market and regional alignment initiative expected to bring about $20 million in restructuring charges and about $30 million in annualized savings.
Q4 fiscal 2025 revenue $330.6 million, down 3.7%; organic revenue down 0.2%, with Plasma down 9.1% and Blood Center down 22.2%
Q4 GAAP EPS $1.17 vs $0.40; adjusted EPS $1.24, up 37.8%
Fiscal 2026 guidance: adjusted EPS $4.70 to $5.00, adjusted operating margin 26% to 27%, free cash flow $160 million to $200 million
Alignment initiative: about $20 million in charges, mostly cash, through fiscal 2027; about $30 million annualized savings once complete
Haemonetics appointed Frank W. Chan, Ph.D., former President of Medtronic's Acute Care & Monitoring business, as Executive Vice President and Chief Operating Officer, effective April 7, 2025, and promoted Roy Galvin to Executive Vice President and Chief Commercial Officer effective immediately. The filing describes these as leadership changes in the executive team; it reports no financial results or guidance, so it does not change reported figures.
Frank W. Chan, Ph.D., 55, starts as COO on April 7, 2025, overseeing R&D, regulatory, global manufacturing and supply chain, and reporting to CEO Christopher A. Simon
Chan's pay includes a $550,000 base salary, a target bonus of 80% of base salary, and a long-term equity award target value of $1,600,000, subject to Compensation Committee approval
Chan receives a $350,000 sign-on bonus, with $300,000 repayable in the first 12 months and $150,000 repayable between months 12 and 24 if he leaves voluntarily or is terminated for cause
Roy Galvin's expanded CCO role covers Global Hospital, Global Plasma and Blood Center; Stewart Strong, President, Global Hospital, stays in his role through April 1, 2025, then advises the CEO temporarily
Haemonetics reported third-quarter fiscal 2025 revenue of $348.5 million, up 3.7%, and GAAP earnings of $0.74 per diluted share, up from $0.61. The company lowered its fiscal 2025 reported revenue growth guidance to 3% to 5% from 5% to 8% and cut free cash flow guidance to $120 million to $140 million from $130 million to $180 million, while narrowing its adjusted earnings per share guidance to $4.50 to $4.70.
Third-quarter revenue was $348.5 million, up 3.7%, while organic revenue decreased 0.3%.
GAAP earnings per diluted share were $0.74, versus $0.61 a year earlier; adjusted earnings per diluted share were $1.19, up 14.4%.
Fiscal 2025 reported revenue growth guidance was lowered to 3% to 5% from 5% to 8%.
Free cash flow guidance was cut to $120 million to $140 million from $130 million to $180 million; adjusted earnings per share guidance was narrowed to $4.50 to $4.70 from $4.45 to $4.75.
Haemonetics said Executive Vice President of Global Manufacturing and Supply Chain Josep Llorens will retire effective July 11, 2025. He will stay in his role while the company searches for a successor and will help the CEO with the transition until he leaves. The change involves a named executive officer in charge of manufacturing and supply chain, but the filing gives no financial impact.
Josep Llorens, Executive Vice President, Global Manufacturing and Supply Chain, will retire effective July 11, 2025
Llorens will remain in his current role while the company searches for a successor
Llorens will assist CEO Christopher A. Simon with the transition until his retirement
Haemonetics reported second-quarter fiscal 2025 revenue of $345.5 million, up 8.6%, and GAAP diluted EPS of $0.66, up from $0.48 a year earlier. The company reaffirmed its fiscal 2025 adjusted EPS guidance of $4.45 to $4.75, while its organic revenue growth guidance was raised to 1% to 4% from 0% to 3%, and operating cash flow fell to $48.8 million from $99.1 million.
Q2 fiscal 2025 revenue was $345.5 million, up 8.6%; organic revenue rose 3.7%
GAAP net income was $33.8 million, or $0.66 per diluted share, versus $24.9 million, or $0.48, a year earlier
Adjusted EPS was $1.12, up 13.1%; fiscal 2025 adjusted EPS guidance of $4.45 to $4.75 was reaffirmed
Operating cash flow was $48.8 million versus $99.1 million, and free cash flow was $37.0 million versus $75.0 million
Haemonetics disclosed that Anila Lingamneni, Executive Vice President and Chief Technology Officer, will leave the company on November 1, 2024. The filing describes her as a named executive officer and gives no successor or reason for the departure.
Anila Lingamneni, Executive Vice President and Chief Technology Officer, will leave on November 1, 2024
The departure is listed under Item 5.02 for a named executive officer
The filing does not name a successor or give a reason for the departure
The 8-K was signed by CEO Christopher A. Simon on September 16, 2024
Haemonetics reported first quarter fiscal 2025 results for the period ended June 29, 2024, with revenue up 8.0% to $336.2 million, while GAAP earnings per diluted share fell to $0.74 from $0.80 and adjusted earnings per diluted share fell 2.9% to $1.02. The company reaffirmed its fiscal 2025 revenue, adjusted operating margin, adjusted earnings per share and free cash flow guidance, so shareholders see stronger sales but lower profit in the quarter with no change to the full-year outlook.
Revenue was $336.2 million, up 8.0% from the prior year; organic revenue grew 2.8%, with Hospital up 30.7% and Plasma down 2.7%.
GAAP operating income was $39.8 million, an 11.8% margin, versus $53.7 million and a 17.2% margin a year earlier.
Operating cash outflow was $27.4 million and free cash outflow was $16.9 million, compared with operating cash inflow of $19.1 million a year earlier.
Fiscal 2025 adjusted earnings per diluted share guidance of $4.45 to $4.75 was reaffirmed.
Haemonetics completed the issuance of $700 million of 2.50% convertible senior notes due June 1, 2029 on May 28, 2024, including $100 million from the full exercise of the initial purchasers' option. The company used the proceeds to pay $88.2 million for capped call transactions, repurchase $200.0 million of its 0.00% convertible notes due 2026 for $185.5 million in cash, and repay the $230.0 million revolving credit balance in full.
$700 million of 2.50% convertible senior notes due June 1, 2029, issued May 28, 2024
Initial conversion price of about $117.12 per share; capped call cap price initially $180.18
Proceeds: $88.2 million for capped calls, $185.5 million to repurchase $200.0 million of 2026 notes, $230.0 million revolver repaid
Notes are senior unsecured obligations; interest payable semi-annually beginning December 1, 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Haemonetics filing is on SEC EDGAR ↗. 8-K briefs of other companies →